Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$543000.0.

  • Editas Medicine's Change in Accured Expenses fell 15349.75% to -$543000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 141893.78%. This contributed to the annual value of $11.6 million for FY2024, which is 18252.31% up from last year.
  • Per Editas Medicine's latest filing, its Change in Accured Expenses stood at -$543000.0 for Q3 2025, which was down 15349.75% from $578000.0 recorded in Q2 2025.
  • Editas Medicine's Change in Accured Expenses' 5-year high stood at $17.1 million during Q4 2024, with a 5-year trough of -$9.6 million in Q1 2021.
  • For the 5-year period, Editas Medicine's Change in Accured Expenses averaged around $1.3 million, with its median value being $1.0 million (2024).
  • As far as peak fluctuations go, Editas Medicine's Change in Accured Expenses soared by 190582.19% in 2021, and later plummeted by 28878.77% in 2024.
  • Editas Medicine's Change in Accured Expenses (Quarter) stood at $5.3 million in 2021, then skyrocketed by 108.42% to $11.0 million in 2022, then tumbled by 62.77% to $4.1 million in 2023, then soared by 319.01% to $17.1 million in 2024, then crashed by 103.17% to -$543000.0 in 2025.
  • Its last three reported values are -$543000.0 in Q3 2025, $578000.0 for Q2 2025, and $1.7 million during Q1 2025.